Alimera Sciences Inc (ALIM)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
ALIM Chart
Alimera Sciences (ALIM) Soars 6.6%: Is Further Upside Left in the Stock?
Alimera Sciences (ALIM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates
Alimera Sciences (ALIM) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.44 per share a year ago.
SHAREHOLDER ALERT: Weiss Law Investigates Alimera Sciences, Inc.
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alimera Sciences, Inc. ("Alimera" or the "Company") (NASDAQ:ALIM), in connection with its acquisition by ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). Under the merger agreement, the Company's shareholders will receive $5.50per share in cash at closing and one non-tradable contingent value right ("CVR") to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027.
Alimera Sciences Inc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JL Jeremiah Ludington Mainstay Capital Management LLC /ADV | 1,038.5 | $15,500.23 | $0.6 | -$15,499.63 | -100% |
Alimera Sciences Inc (ALIM) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Alimera Sciences Inc Profile
| - Industry | - Sector | Mr. Richard S. Eiswirth Jr. CEO | NASDAQ (NMS) Exchange | 016259202 CUSIP |
| United States Country | 154 Employees | - Last Dividend | 15 Nov 2019 Last Split | 22 Apr 2010 IPO Date |
Overview
Alimera Sciences, Inc. is a specialized pharmaceutical company dedicated to the development and commercialization of prescription ophthalmic retinal pharmaceuticals. The company has established its operations across different segments, including the United States and International markets, in addition to its Operating Cost segment. The focus of Alimera Sciences is on offering innovative treatments for severe retinal diseases that can lead to significant vision loss or blindness, particularly among diabetic individuals. Since its incorporation in 2003 and based in Alpharetta, Georgia, the company has focused on addressing the needs of patients suffering from diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). Through strategic collaborations, such as with EyePoint Pharmaceuticals US, Inc. and Ocumension (Hong Kong) Limited, Alimera Sciences aims to extend its reach and enhance the availability of its treatments globally.
Products and Services
-
ILUVIEN:
This is a fluocinolone acetonide intravitreal implant designed for the treatment of diabetic macular edema (DME), a condition affecting the retina which can result in severe vision loss or even blindness in diabetic patients. ILUVIEN is also approved for use to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It represents a significant advancement in the management of these conditions by providing a long-term treatment option.
-
YUTIQ:
YUTIQ is another fluocinolone acetonide intravitreal implant, specifically designed for the treatment of non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). This product is a result of Alimera Sciences’ collaboration with EyePoint Pharmaceuticals US, Inc., underlining the company’s commitment to addressing unmet medical needs in the field of retinal diseases through innovative therapeutic solutions.
In addition to developing these innovative pharmaceutical products, Alimera Sciences engages in a comprehensive sales strategy. The company sells its products through a mix of direct sales and distributors, targeting physician offices, clinics, pharmacies, and hospitals to ensure that patients in need have access to their treatments. This approach supports physicians in managing complex retinal diseases effectively, thereby enhancing patient care outcomes.
Contact Information
